Back

Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia identified through universal lipid screening: association with pathogenic variants

31 August 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Lipoprotein(a) (2) Lipids ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ryosuke Tani

Kagawa University Faculty of Medicine, Kagawa (Japan)

5 More presentations in this session

Presentation thumbnail
A systematic review of lipoprotein(a) reporting in Australia: variability in availability, measurement, and clinical recommendations
Doctor R. Ma (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Apolipoprotein B/LDL-C discordance and lipoprotein(a) as predictors of ASCVD risk in genetically confirmed heterozygous familial hypercholesterolemia (HeFH): A Retrospective Cohort Study (2005–2023)
Doctor N. Genedy (Cardiff, GB) Doctor S. Zouwail (Cardiff, GB)
Abstract Slides Video
Presentation thumbnail
Comparison of lipoprotein (a) levels in patients with a history of coronary artery disease and in normal subjects
Doctor T. Okada (Takamatsu, JP)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) testing in Norway: trends and perspectives from primary care
Ms J. Jeevanathan (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Variability of lipoprotein(a) concentrations in a cohort of patients enrolled in a cardiac rehabilitation program after an acute coronary syndrome
Ms A. Diaz Rojo (Toledo, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Lipoprotein(a) (2)

The Event

Event poster

ESC Congress 2025

31 August 2025 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study
thumbnail
Congress Presentation
What is new regarding lipoprotein(a)
thumbnail
Congress Presentation
Can the association between LDL-Cholesterol and incident coronary heart disease (CHD) be modulated by concomitant Lp(a) levels in the general population?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources